|Day Low/High||0.70 / 0.73|
|52 Wk Low/High||0.49 / 3.59|
Aveo's Tivozanib kidney cancer drug will get the nod from regulators.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Ahead of Thursday's FDA panel, the agency asks if Aveo should conduct a second clinical trial.
It's a big week for Aveo and Delcath, starting Tuesday with FDA reviews of their respective cancer products.
Cramer is keeping up with earnings all week and the unemployment numbers Friday.
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
A close examination of survival data from Aveo's phase III study raises concerns.
TheStreet Sr. Columnist Adam Feuerstein says FDA reviews for cancer drugs from Aveo and Delcath are the next big thing in biotech.
Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
A list of stock-moving biotech catalysts includes FDA drug approvals, clinical trial results and closely-followed medical meetings.
Contestants in TheStreet's FDA Drug Approval Contest think well of Sarepta, Navidea and Biogen, less so about Arena, Aveo and Delcath.
AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Barclays Global Healthcare Conference on Wednesday, March 13, 2013 at 9:00 a.
Who will be the premier prognosticator of FDA drug approvals in 2013?
AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Global Development, Inc.
AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the 2013 RBC Capital Markets’ Healthcare Conference on Wednesday, February 27, 2013 at 2:00 p.
New survival data from the phase III study of Aveo's tivozanib were released Tuesday night.
AVEO Oncology (NASDAQ:AVEO) and Astellas Pharma Inc. (TSE:4503) today announced overall survival (OS) for tivozanib, an investigational agent, from the Phase 3 TIVO-1 ( TIvozanib Versus s Orafenib in 1 st line...
New survival data on Aveo's tivozanib to be presented at a medical meeting next week.
AVEO Oncology (NASDAQ:AVEO) today announced that financial results for the company’s fourth quarter and year ended December 31, 2012 will be released before the market opens on Wednesday, February 13, 2013.
AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that new clinical data on tivozanib, an investigational agent for the treatment of metastatic renal cell carcinoma (mRCC), will be ...
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reported that it has closed its recently announced public offering of common stock.
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that the underwriters of its recent public offering of common stock have exercised their option to purchase an additional 1,000,050 shares, the full amount of...
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced the pricing of an underwritten public offering of 6,667,000 shares of its common stock at a price of $7.
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has commenced an underwritten public offering of shares of its common stock.
Live coverage of biotech and drug companies presenting at the J.P. Morgan Healthcare Conference.
A preview of what to expect from biotech stocks at the next week's 'Life Sciences Lollapalooza.'
TheStreet's Adam Feuerstein gazes into his crystal ball to offer his 2013 biotech stock forecast.
AVEO Oncology (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 31 st Annual J.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.